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Background: Radiogenic second cancer is a common late effect in long term cancer survivors. Currently there are
few methods or tools available to visually evaluate the spatial distribution of risks of radiogenic late effects in the
human body. We developed a risk visualization method and demonstrated it for radiogenic second cancers in
tissues and organs of one patient treated with photon volumetric modulated arc therapy and one patient treated
with proton craniospinal irradiation.
Methods: Treatment plans were generated using radiotherapy treatment planning systems (TPS) and dose information
was obtained from TPS. Linear non-threshold risk coefficients for organs at risk of second cancer incidence were taken
from the Biological Effects of Ionization Radiation VII report. Alternative risk models including linear exponential model
and linear plateau model were also examined. The predicted absolute lifetime risk distributions were visualized together
with images of the patient anatomy.
Results: The risk distributions of second cancer for the two patients were visually presented. The risk distributions varied
with tissue, dose, dose-risk model used, and the risk distribution could be similar to or very different from the dose
distribution.
Conclusions: Our method provides a convenient way to directly visualize and evaluate the risks of radiogenic
second cancer in organs and tissues of the human body. In the future, visual assessment of risk distribution could
be an influential determinant for treatment plan scoring.
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Radiation therapy has long been used as an effective
treatment for malignancies in cancer patients. However,
for many patients, the late effects of radiation (e.g., sec-
ond cancers, cardiac toxicities, reductions in fertility,
bone growth abnormalities, and cognitive deficits) re-
duce their survival time and/or quality of life after treat-
ment [1-3]. With increasing long-term survival rates in
cancer patients [4], avoiding treatment-related late ef-
fects is increasingly important [5]. Second cancers are of
particular concern because of their high incidence and
they account for about 16% of all cancers in the United
States [6]. A majority of second cancers are malignant
and these are difficult to control [7]. To develop* Correspondence: rzhang@marybird.com
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unless otherwise stated.strategies to minimize radiogenic second cancer, we
must first be able to routinely predict patients’ risks of
developing second cancers, which has not become feas-
ible until recently because of limitations in dose recon-
struction methods and dose-risk models [8].
Currently, clinicians evaluate the quality of a radiation
therapy by inspection of the treatment plan generated by
modern treatment planning systems (TPSs), including
prescription dose to the target, dose distribution overlaid
on the patient’s images, dose volume histograms, and
other dosimetric figures-of-merit, such as the dose
homogeneity index [9], conformity index [10], normal
tissue complication probability (NTCP) [11], and tumor
control probability [12]. Among those measures, only
spatial dose distributions can be visually checked in two
or more dimensions simultaneously, which provides very
valuable information, such as the anatomic location of
dose hot and cold spots. The NTCP and other commonlyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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they only provide a single numerical value. There has been
progress in studies of risks of radiogenic late effects in re-
cent years [13-19], but the investigation of the spatial dis-
tribution of risks in the human body is limited to a few
groups [5,20,21].
In this work, we developed methods to visualize the
risk of radiogenic second cancer for patients, taking into
account treatment factors (e.g., dose, beam direction)
and host factors (e.g., sex and age at exposure). We dem-
onstrated the feasibility of this method by creating treat-
ment plans for two patients undergoing photon and
proton therapies using commercial TPSs, converting ra-
diation doses from the TPSs to the risks of radiogenic
second cancer using dose-risk models from the litera-
ture, and displaying the risk distributions superimposed
on the patient’s computed tomography (CT) images.
The limitations and uncertainties associated with risk
visualization were also examined.
Methods
Patients and treatment techniques
The first patient was a 67-year-old man diagnosed with
moderately differentiated adenocarcinoma of the pros-
tate, received prostatectomy and treated with volumetric
modulated arc therapy (VMAT) at Mary Bird Perkins
Cancer Center. Three-dimensional CT images were ac-
quired with 2.5-mm thick slices from the waist to the
thigh. The VMAT plan was created using a commercial
TPS (Pinnacle, Philips Medical Systems, Fitchburg, WI).
The dose prescription was 68 Gy administered in 2 Gy/
fraction to the prostate bed. Two 6-MV overlapping
350° arcs were utilized, with a 45° collimator angle for
both. The organs at risk for this patient included the
bladder, rectum, prostate, and remainder (i.e., all other
tissues/organs) as specified by the report of the commit-
tee on the Biological Effects of Ionizing Radiation (BEIR
VII) [22]. Because the risk coefficient was provided for
the whole colon in BEIR VII and the rectum is only part
of the colon and because only part of the whole body
was scanned, the risks for the rectum and remainder
were scaled down by mass fractions as we previously re-
ported [23], i.e., we divided the mass of rectum by the
mass of whole colon, and divided the mass of remainder
in the current CT data by the mass of total body which
can be obtained from patient’s record.
The second patient was a 13-year-old girl diagnosed
with medulloblastoma and treated with surgical resec-
tion and passively scattered proton therapy at the Uni-
versity of Texas MD Anderson Cancer Center. The
patient was treated with craniospinal irradiation (CSI)
of 21.3 Gy administered in 1.64 Gy/fraction. A CT scan
with 2.5-mm-thick slices was obtained from the top of
the head to the thigh. The proton treatment plan wascreated using a commercial TPS (Eclipse, Varian Medical
Systems, Palo Alto, CA). The plan contained five fields:
right and left posterior oblique cranial fields and three
posterior-anterior spinal fields. The organs of interest in-
cluded stomach, colon, lungs, bladder, thyroid, breast,
liver, uterus, ovary, and remainder. The risk for the re-
mainder was scaled down by a mass fraction because the
CT scan did not include anatomy below the thigh.
Both patients’ data were exported from TPS and anon-
ymized [24] for research purpose. Only primary doses
reported by TPS were used in risk estimations.
Risk estimation and visualization
In the traditional approach cancer risk was estimated
from radiation exposure for radiation protection pur-
pose, which has been adopted by several authors for
second cancer risk estimation after radiation therapy
[25,26], the risk of second cancer for each organ/tissue
was calculated as
RT ¼ HT  RH
 
T




where RT is the risk in tissue T, HT is the mean equiva-
lent dose in tissue T, DT is the mean organ dose calcu-
lated by the TPS and wR is the mean radiation weighting
factor (1.1 for proton beams and 1 for photon beams).
The reasons to use 1.1 for proton radiation weighting
factor are: 2 was recommended for general use and in-
cluded very high proton energies near 1 GeV from cos-
mic radiation [27,28]. While for proton therapy, the
highest energy is around 200 MeV and the LET for these
protons is less than 10 keV/μm [27]. The mean quality
factor is around 1.1 for 150 MeV protons [27,28]. Taking
these into account, we think it is more appropriate to
use 1.1 than 2 as the mean radiation weighting factor for
therapeutic protons. RH
 
T is the organ-specific relative
or absolute risk coefficient taken from tables 12D-1 in
the published BEIR VII report [22] and the dose and
dose-rate reduction (DDREF ) factor (1.5) was taken out
because we are studying risks after high dose radiother-
apies. For brevity, we discuss only lifetime absolute risk of
cancer incidence in this paper although the methods could
be applicable to arbitrary time point and endpoints.
However, Dorr and Herrmann [29] and Diallo et al
[30] reported most of the second cancer tumors were
localized within the border of the irradiated volume in-
stead of uniformly distributed within the organ/tissue.
These findings showed that a mean organ dose should
not be used to calculate risk of second cancer when
there is a dose heterogeneity within the organ. We cal-
culated risk using an in-house code (based on MATLAB
software, Mathworks, version 7.9, Natick, MA) and a
voxelized phantom based on each patient’s data (Figure 1).
Figure 1 Schematic illustration of risk estimation method (using LNT dose-risk model) based on a voxelized phantom.
Figure 2 Flow chart for risk estimation and visualization.
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First, the patient-related data, including CT images,
RTDose and RTStructure files were read in Digital
Imaging and Communication in Medicine (DICOM)
format by the in-house code. The code generated three-
dimensional dose and CT matrices. Second, each voxel in
the three-dimensional dose matrix was uniquely assigned
to one organ/tissue by comparing the coordinates of that
voxel with the coordinates of organs in the RTStructure
file which contains all the structure contour information.
Third, by applying a linear non-threshold (LNT) dose-risk
model, taking into account patient’s sex and age at ex-












where HTi is the equivalent dose in the ith voxel, and
NT,voxel is the total number of voxels in the organ. The
spatial distribution of the risk was superimposed on the
CT images as a color overlay. Figure 2 schematically
shows the methods for risk estimation and visualization.
Dose-risk relationships are uncertain below approxi-
mately 50 mSv and above approximately 2.5 Sv, e.g., at
high therapeutic doses. At low doses, we shall assume a
LNT behavior. At high doses, cell sterilization mecha-
nisms may be effective, and some dose-risk relationships
(e.g., linear-plateau [LPLA] and linear-exponential [LEXP]
relationships [21,31,32]), may describe the radiobiological
outcomes better than a linear model. For example, there is
strong evidence that the dose-risk relationship for thyroid
is not linear [33-35]. Therefore, in order to explore the
possible influence of non-linear behaviors on risk
visualization, these alternative dose-risk models were
also applied in addition to the LNT model used in theBEIR VII [22] when we calculated and displayed risks.
The LNT model was used as a baseline model. For the













where δ is a cell sterilization parameter, DTi are the
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fined for cell killing deterministic effects [27] and is 1
for photon and 1.1 for proton [36]. For the LEXP model,












where α is a cell sterilization parameter. Numerical
values for α and δ were determined heuristically to ob-
tain the correct form, i.e., they were iteratively adjusted
so the dose response curves will bend at certain dose
value [14,37].
Unlike absorbed dose (an intrinsic quantity), the
spatial visualization of risk (an extrinsic quantity) distri-
butions depends on the voxel size used. The “absolute
risk” in any voxel could be very small if there are a large
number of voxels in the organ that voxel belongs to be-
cause the risk coefficient is defined for the whole organ,
and RH
 
T=NT ;voxel would be small if NT,voxel is large. Al-
though this does not affect the final whole-organ risk, it
can complicate the visualization of risk distributions.
This “voxel-size problem” increases in severity with in-
creasing organ size, decreasing RH
 
T, decreasing voxel
size and decreasing dose. To overcome this problem, we
color-coded risks by organ and visualized spatial distri-
butions of “risk gradient” by the degree of transparency
of the risk colorwash.
Results
Figure 3 shows the distributions of equivalent doses and
lifetime risks of incidence of second cancer based on
different dose-risk relationships (LNT, LPLA(10), and
LEXP(10)); the number in the parentheses refers to 10
Sv, the value beyond which risk becomes non-linear
with dose, following the methods of previous study [37].
When we used the LNT model, the predicted lifetime
risks of second cancer incidence were 32.3% for the
bladder, 18.3% for the prostate, 10.4% for the rectum,
and 5.2% for the remainder (Figure 3b). The risk distri-
butions were starkly different from the dose distribu-
tions (Figure 3a) for all the risk models considered.
Risks were high in high-dose regions when the LNT
model was applied, whereas risks decreased in the high-
dose regions when the LPLA or LEXP models were ap-
plied, and this was especially true for the LEXP(10)
model (Figure 3d). For example, in the bladder, the risk
distributions were reversed when the LEXP(10) model
replaced the LNT model because risk decreased after 10
Sv, whereas the risk distribution in the bladder was al-
most uniform when LPLA(10) was used because the risk
plateaued after 10 Sv (Figure 3c).Figure 4 shows the distributions of the doses and life-
time risks of incidence of second cancer based on dose-
risk relationships (LNT, LPLA [5], LEXP [5]); the number
in the brackets is the equivalent dose in unit of Sv, the
value beyond which risk becomes non-linear with dose,
which was chosen for the second patient who received
proton CSI (some organs of interest cannot be seen on
the slices presented here) follow the methods in previous
study [14]. According to the LNT model, the lifetime risks
were 15.4% for the remainder, 13% for the lung, 1.8% for
the thyroid, 0.1% for the colon, 0.1% for the liver, and
0.02% for the stomach (Figure 4b). The risks for bladder,
breast, uterus and ovary were 0 because doses to those or-
gans were 0. When the LNT or LPLA (Figure 4c) model
was applied, the shapes of the dose and risk distributions
were similar, where the differences were caused by varia-
tions in the radiosensitivity of various organs of tissues.
However, the risk distribution was very different from
dose distribution when the LEXP model was applied when
risks decreased after 5 Sv (Figure 4d).
Discussion
In this study, a method was developed to visualize the
predicted risk of radiogenic second cancer for patients
who received radiation therapy: one patient received
photon VMAT and the other received proton CSI. The
dose distributions were extracted from treatment plans,
and risks were calculated and superimposed on the pa-
tients’ CT images.
The apportionment of whole-organ risk to voxelized
subvolumes of the organ according to Eq. (2), (3) and (4)
is the simplest and most consistent approach to generalize
the whole-organ risk models used from the epidemiology
literature. This very simple apportionment approach does
not attempt to describe possible variations in myriad and
complex mechanisms in carcinogenesis that may occur
across an organ or tissue. Stated another way, we did not
attempt to model spatial variations in risk coefficients
themselves across an organ or tissue. Strictly speaking, be-
fore new risk models with finer spatial resolution come
out, one cannot calculate risk in each voxel. Rather, for
the intents and purposes of this work, we used widely
used risk models and simple risk apportionment methods
to learn about how radiation dose gradients influence the
visualization of risk. In particular, we focused on a vexing
problem related to visualizing spatial distributions of risk
gradient, which are extrinsic. That said, it is possible that
radiation sensitivity varies across an organ or tissue, e.g.,
due to variations in concentration of potential clonogens,
oxygen, repair capacities, and other factors. In principle, if
such dependencies can be observed and modeled, this
could be used to refine the risk apportionment method in
this study. To our knowledge, there is insufficient know-
ledge to implement such refinements at this time.
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Figure 3 Visualization of (a) equivalent dose and (b), (c), and (d) lifetime risks of second cancer incidence based on different dose-risk relationships
(LNT: linear non-threshold model, LPLA(10): linear plateau model with bending point at 10 Sv, LEXP(10): linear exponential model with bending point
at 10 Sv) on sagittal and coronal slices for a 67-year-old man who received photon VMAT prostate treatment.
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Figure 4 Visualization of (a) equivalent dose and (b), (c), and (d)
lifetime risks of second cancer incidence based on different dose-risk
relationships (LNT: linear non-threshold model, LPLA(5): linear plateau
model with bending point at 5 Sv, LEXP(5): linear exponential model
with bending point at 5 Sv) on a sagittal slice for a 13-year-old girl
who received proton CSI.
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group [20,21,38], utilized a similar method to show sec-
ond cancer risk distribution in the regions where second
cancers had developed. Basically they showed a normal-
ized relative risk map in different regions (organs) while
we showed absolute risks. As they pointed out in their
paper [20] and as we mentioned in our manuscript, their
way of displaying risk distribution suffered from the
“voxel-size problem” because the “voxelized risk” value
for a larger organ will be small and difficult to visualize.Again, due to the limitation of current dose-risk models,
the definition of “voxelized risk” has a conceptual prob-
lem. To overcome this limitation, in the present study, the
risks were color-coded by organ and spatial distribution of
risk gradient was visualized by the degree of transparency
of the risk colorwash. In this way, the organ specific risks
can be assessed quickly (each organ has a different color)
and detailed assessment of sub-regions of the individual
organs can be visualized clearly. Regardless of the differ-
ences between our study and theirs, their qualitative
finding was consistent with ours in that the risk was
concentrated at the edges of the high-dose region when
the LEXP model was used, and the risk was concentrated
in the high-dose area when the LPLA model was used.
Dorr and Herrmann [29] studied a sample of patients
who developed second tumors from a cohort of about
31000 cancer patients who received radiotherapy in
Germany between 1969 and 1989. They reported that
most of the second tumors occurred in volumes receiv-
ing < 6 Gy and were seen within the margin region of
the treatment volume (2.5 cm inside to 5 cm outside the
50% isodose line). Diallo et al [30] also studied a sample
of patients with second cancers from a cohort of 4581
patients who were irradiated between 1942 and 1986 at
8 French and United Kingdom centers, and they re-
ported that the majority of second solid cancers ap-
peared in low- or intermediate-dose regions (<2.5 Gy)
bordering the irradiated volume. Based on this infor-
mation and the risk distributions for the 2 patients in
this study, it appears possible that the LEXP model
may provide the qualitatively closest result compared
with aforementioned observational evidence. On the
other hand, epidemiologic study like Berrington de
Gonzalez et al [39] reported that second cancer risk
kept increasing even at organ doses higher than 60 Gy,
except thyroid cancer which clearly showed a downturn
after 20 Gy. Further studies still need to be carried out to
test these findings. Our risk visualization methods and
software platform can be used for research on this and
other aspects of risk prediction and visualization.
One limitation of this work was the availability of dose-
risk models that are valid at therapeutic doses. Currently,
there is no consensus on what model should be used for
organs or tissues that receive high primary radiation doses
except thyroid. Many researchers have argued that the
BEIR VII models and other similar models were developed
for low doses and low dose rates and some have proposed
alternative dose-risk models [40-43]. However, these new
risk models are either still under development or less well
established and validated. The “voxel-size problem,” which
we mentioned in the methods section of this report, is also
due in part to the limitation of available risk models which
only provide risk coefficients for whole organs. And as
Pfaffenberger et al [20] pointed out, it is problematic to
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individual size of the patient’s organ while the risk coeffi-
cients was defined using a mean organ size. Risk models
with finer spatial resolution and improved accuracy are
needed. Development of the latter will require large sam-
ples of radiation therapy patient data for which accurate
dose distributions and cancer incidence are available. Fur-
thermore, our results suggest that the extrinsic nature of
risk distributions and the uncertainties in risk models
comprise significant research challenges that must be ad-
dressed before risk visualization methods are adopted as
clinical decision support tools. However, the basic risk
visualization methodology proposed in this study is applic-
able to arbitrary risk models, and addition risk models can
be incorporated into our code system in a straightforward
manner. The other limitation in this study is that we as-
sumed tissue density in each voxel is the same within an
organ. This is not a serious limitation for the purposes
of this study because density variation within one organ
is small for most organs except lung, and an enhance-
ment of the code by including three-dimensional voxel
density information is in progress. In the future, when
risk models with finer spatial resolution are developed
or cell level risk coefficients are available, not only tissue
density but also tissue/cell type need to be taken into
account for risk estimations.
The strengths of this study include the fact that we in-
vestigated clinically-relevant advanced-technology radi-
ation treatment modalities and techniques. We used
realistic patient data from the two most commonly used
commercial TPSs in different institutions. The results of
this study are significant because they conceptually dem-
onstrate that risks of radiogenic side effects cannot be
assessed by visualizing dose distributions and offer direct
spatial information about risks, which cannot be obtained
from single mean organ risk values or other scalar quan-
tities. Eventually, the visualization of risk distributions in
the human body may become an essential part of the
treatment planning, particularly for young patients with
good prognoses for long term survival.
Despite the importance of second cancer, the short-term
treatment outcome - the primary cancer control - should
not be compromised by the consideration of late effects.
The primary cancer control remains the highest priority.
However, the risks of late effects are often neglected in
contemporary treatment planning methods. Risk evalu-
ation of late effects is especially important for pediatric
patients who have good prospect to survive their pri-
mary cancer but may suffer from radiogenic late effects.
Calculating and displaying the risks of other late effects,
such as cardiac toxicity etc., would be the next logical
step. In addition, besides primary dose, stray radiation
doses should be included because most second cancers
occur in low- or medium-dose areas [29,30]. MonteCarlo techniques [13], measurements [44], or analytical
models [45,46] should be used to assess stray doses be-
cause current TPSs cannot calculate them accurately.
Although color scales and degrees of transparency were
used in this paper, “iso- risk gradient” lines could also
be used in a similar manner, i.e., using solid line for the
highest risk, dashed line for the second highest risk, dot
dashed for the third highest risk, and so on. Our method
for risk estimation and visualization can be incorporated
into current commercial TPSs in a straightforward man-
ner and could in principle be used for personalized patient
risk assessments, algorithmic optimization of treatment
plans by taking into account radiogenic late effects [47],
and to supplement the physicians’ judgment of treatment
modality selection.
Conclusion
In summary, we have developed and demonstrated a
new method to visualize the risk of radiogenic second
cancers. This tool allows direct visualization and quantita-
tive assessment of the risks of radiogenic second cancer,
including the mean organ risk, spatial distribution of risk
within organs, and possible variations of the risk value
and distribution by taking uncertainties into account. It
also revealed the current limitations of the risk estimation
due to the extrinsic nature of the spatial risk distributions
and non-linearity in dose response models. It may also be
used to guide the development of future dose-risk models,
and predict the distribution of second cancer and other
radiogenic late effects after both conventional and modern
radiation treatments.
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